Approval · Notice of Compliance 13516 · 2012
CRIXIVAN: Notice of Compliance 13516
Issued July 26, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13516
- Date
- July 26, 2012
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- ALternate manufacturing site
- Therapeutic class
- HIV Protease Inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CRIXIVAN | Not yet assigned | — |
Medicinal ingredients
- INDINAVIR SULFATE 200 MG per CAP
- INDINAVIR SULFATE 400 MG per CAP